The research initiative generating these leads, Beat AML, is led by
the Knight Cancer Institute at Oregon Health & Science University
and The Leukemia & Lymphoma Society (LLS). Beat AML brings together
academic health centers and biopharmaceutical companies to accelerate
discoveries that will improve outcomes for patients with acute myeloid
leukemia (AML), a blood cancer lacking effective treatments. Less than
25 percent of newly diagnosed patients survive beyond five years.
A total of nine pharmaceutical and biotech companies have joined the
collaboration, providing 27 potential treatments for analysis on the
research platform. Recent additions are: argenx; AstraZeneca;
Genentech; Janssen Research & Development, LLC; Seattle Genetics;
and Takeda Pharmaceuticals International Co. Among the participants
that joined early on are Aptose Biosciences and Constellation
Pharmaceuticals.
"Acute myeloid leukemia is now the most frequently diagnosed
leukemia in adults, while the current standard of care is based on
40-year-old chemotherapy agents with a very poor cure rate," said Louis
J. DeGennaro, Ph.D., LLS's president and CEO. "LLS, together with its
partners in the Beat AML collaboration, has gone on the offense against
this deadly disease to lead the way to new treatment options desperately
needed by patients."
No comments:
Post a Comment